



Ami Organics Limited

CIN. : L24100GJ2007PLCO51093

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

October 29, 2024

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code : 543349

NSE Symbol : AMIORG

Subject: Investor Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on second quarter and half year ended financial results as on September 30, 2024 and other business matters.

This Investor Presentation will also be available on the website of the Company
www.amiorganics.com.

Kindly take the same on record.

Yours faithfully,
For, **AMI ORGANICS LIMITED**

Ekta Kumari Srivastava
Company Secretary & Compliance Officer



Encl: Presentation



Info@amiorganics.com



www.amiorganics.com



+91 72279 77744 / 75730 15366

Investor Presentation

OCTOBER 2024

BSE : 543349 | NSE : AMIORG | www.amiorganics.com



AMI ORGANICS LTD.

Table of Contents

01

Q2 & H1FY25 Results

02

Company Overview

03

Advanced Pharma
Intermediate

04

Specialty Chemicals

05

Working towards better
tomorrow

1. Q2 & H1FY25 Results

- Management Commentary
- Q2FY25 Earnings Highlights
- Q2FY25 Business Highlights
- Q2FY25 Financial Performance – Key Metrics
- H1FY25 Financial Performance – Key Metrics
- Q2 & H1FY25 Financial Performance – P&L Statement
- Financial Performance over the years – Key Metrics
- Financial Performance over the years – Profit and Loss
- Financial Performance over the years – Balance Sheet
- Shareholder Information





Mr. Naresh Patel
Executive Chairman and Managing Director

Management Commentary

"Despite ongoing challenges in the global chemical industry, I am pleased to report stellar year-over-year growth of 43.2% in Q2FY25, driven by exceptional performance in our Pharmaceutical Intermediates and Specialty Chemicals businesses. Our key products maintained growth momentum, and an earlier-than-anticipated ramp-up in our CDMO business provided an additional boost to our results.

I am also proud to announce that PMDA Japan has issued an Inspection Result Report declaring our Sachin Facility as Good Manufacturing Practices (GMP) compliant.

We are experiencing a resurgence in demand for our core molecules, bolstered by ramp up in CDMO contract and strong volume growth within our Specialty Chemicals division. Based on the current order pipeline, we are raising our revenue growth guidance for FY25 from 25% to 30%."

Revenue for Q2FY25
(Mn)

Rs. 2,467

↑ 43.2%
YoY

EBIDTA for Q2FY25
(Mn)

Rs. 489

↑ 97.2%
YoY

PAT for Q2FY25
(Mn)

Rs. 375

↑ 155.0%
YoY



Q2FY25 Earnings & Business Highlights

- **Revenue from operations** for Q2FY25 grew by **43.2% YoY** to **Rs. 2,467 mn**
- The **gross margin** for the quarter improved to **43.4%** up 239 bps YoY and 136 bps QoQ
- **EBITDA** for the quarter came at **Rs. 489 mn** up 97.2% YoY compared to Rs. 248 mn in Q2FY24.
- **EBITDA margin** for the quarter was at **19.8%** as compared to 14.4% in Q2FY24.
- **PAT** for the quarter was **Rs. 375 mn** up 155% as compared to adjusted PAT of Rs. 147mn in Q2FY24
- The **PAT margin** for the quarter was at **15.2%** up 668 bps YoY and 682 bps QoQ
- Export at **76%**; domestic business at **24%**
- Further to the inspection concluded by by Pharmaceutical and Medical Devices Agency, Japan ("**PMDA**") without any critical/major observation, the agency has issued Inspection Result Report **declaring the Sachin Facility as a Good Manufacturing Practices (GMP) compliant.**

Q2FY25 Financial Performance – Key Metrics

Revenue from Operations


(Rs Mn)

YoY Growth

53.1%

7.6%

43.2%



EBITDA & EBITDA Margin

(Rs Mn)

14.4%

248

Q2FY24

EBITDA

19.8%

489

Q2FY25

EBITDA Margin

PAT

(Rs Mn)

8.5%

147

Q2FY24

PAT

15.2%

376

Q2FY25

PAT Margin


Note: PAT, PAT Margin are adjusted for Exceptional Items.

H1FY25 Financial Performance – Key Metrics




Revenue from Operations

(Rs Mn)




EBITDA & EBITDA Margin

(Rs Mn)



PAT

(Rs Mn)



Note: PAT, PAT Margin are adjusted for Exceptional Items.

Q2 & H1FY25 Financial Performance – P&L Statement

Particulars (Rs. Mn)	Q2FY25	Q2FY24	YoY	Q1FY25	QoQ	H1FY25	H1FY24	YoY
Revenue from Operations	2,467	1,724	43.2%	1,767	39.7%	4,234	3,261	29.8%
COGS	1,396	1,016		1,023		2,419	1,817	
Gross Profit	1,072	708	51.5%	743	44.2%	1,815	1,444	25.7%
<i>Gross Margin</i>	43.4%	41.0%		42.1%		42.9%	44.3%	
Employee benefits expenses	196	158		191		387	299	
Other expenses	386	301		258		644	556	
Total Expenses	1,978	1,475		1,472		3,450	2,673	
EBITDA	489	248	97.2%	295	65.8%	784	588	33.4%
<i>EBITDA Margin</i>	19.8%	14.4%		16.7%		18.5%	18.0%	
Depreciation and amortization	68	37	85.0%	62	10.5%	130	74	
PBIT	421	211	99.3%	233	80.4%	654	514	27.3%
Finance costs	5	8		44		49	13	
Other Income	84	15		10		95	27	
Exceptional Item	0	-318		0			-318	
PBT	500	-99		200	150.8%	700	210	233.4%
Tax Expense	125	71		51		177	158	
PAT	376	147	155.0%	149	153.0%	523	370	41.3%
<i>PAT Margin</i>	15.2%	8.5%		8.4%		12.3%	11.3%	

Note: PAT, PAT Margin are adjusted for Exceptional Items.

Financial Performance over the years – Key Metrics

Revenue from Operations- Growth Trends

(Rs Mn)


FY20 FY21 FY22 FY23 FY24 H1FY25

FY20-24 CAGR:

25%

112%


32%



Revenue – by Business Verticals


(Rs Mn)

Pharma Intermediates Specialty Chemicals




Revenue from exports

(Rs Mn)




Financial Performance over the years – Key Metrics (cont'd)


EBITDA and EBITDA Margins (%)




PAT and PAT Margins (%)



Long term Borrowings and Gross Block



Returns Profile



Note: PAT, PAT Margin, ROE and ROCE are adjusted for Exceptional Items.

[#]ROE and ROCE adjusted for outstanding Cash raised in QIP and Preferential Allotment.

Financial Performance over the years - Profit and Loss

Particulars (INR mn)	FY21	FY22	FY23	FY24	H1 FY25
Revenue from Operations	3,406	5,201	6,167	7,175	4,234
Other Income	14	28	43	75	95
Total Income	3,420	5,229	6,210	7,250	4,329
Cost of materials consumed	1,749	2,823	3,459	4,402	2,481
Changes in inventories of finished goods, traded goods and work-in-progress	48	(95)	(150)	(285)	(62)
Employee benefits expenses	210	414	488	631	387
Finance cost	56	64	24	59	49
Depreciation and amortisation expenses	42	101	123	161	130
Other expenses	598	1,008	1,144	1,142	644
Profit before tax and exceptional items	717	914	1,122	1,140	700
Exceptional profit / (loss)	-	-	-	(321)	-
Tax expense	177	195	289	332	177
Profit for the year	540	719	833	487	523

Note: Exceptional item includes full impairment of investment in JV - Ami Oncotheranostics LLC


Financial Performance over the years - Balance Sheet

<i>Assets (INR mn)</i>	FY21	FY22	FY23	FY24	H1 FY25
Property, plant and equipment	1,422	1,584	1,844	3,229	3,171
Right of use assets	184	194	374	372	376
Capital work-in-progress	2	30	255	1,254	1,895
Goodwill	-	-	203	568	568
Other intangible assets	257	267	211	103	92
Investments	14	17	17	2	2
Other financial assets	27	108	65	26	45
Other non-current assets	64	97	129	447	515
Total non-current assets	1,970	2,297	3,098	6,001	6,663
Inventories	604	1,122	1,192	1,567	1,575
Trade receivables	1,207	1,637	2,303	2,064	2,418
Cash and cash equivalents	27	103	305	297	582
Other bank balances	-	893	281	236	2,213
Loans	3	6	13	16	20
Current tax assets (net)	-	49	32	25	57
Other current assets	321	481	445	753	741
Total current assets	2,162	4,291	4,571	4,958	7,606
Total assets	4,133	6,589	7,669	10,959	14,269

<i>Equity and Liabilities (INR mn)</i>	FY21	FY22	FY23	FY24	H1 FY25
Shareholder's equity	1,669	5,223	5,939	6,828	12,118
Borrowings	726	6	6	1,136	26
Provisions	44	4	7	13	21
Deferred tax liabilities (net)	33	63	88	130	142
Total non-current liabilities	803	73	101	1,280	189
Borrowings	640	3	30	1,030	36
Trade payables	848	1,184	1,420	1,346	1,477
Other current liabilities	151	46	64	344	235
Provisions	10	60	114	132	214
Current tax liabilities (net)	11	-	-	-	-
Total current liabilities	1,660	1,293	1,628	2,852	1,962
Total liabilities	2,463	1,366	1,730	4,131	2,151
Total equity and liabilities	4,133	6,589	7,669	10,959	14,269

Shareholder Information

Shareholding as on 30th September 2024



Source: BSE

Share Information as on 30th September 2024

NSE Ticker	AMIORG
BSE Ticker	543349
Market Cap (Rs. Cr)	7,130
Shares Outstanding	4,09,27,511
3M ADTV (Shares)*	2,55,715
3M ADTV (Rs. cr)*	36.93
Industry	Specialty Chemicals

*Source: NSE

2. Company Overview

- Company Overview
- Our Journey
- Our Products
- Strong and Long-term relations with Diversified Customers across Geographies
- Our Manufacturing Facilities
- Superior R&D Capabilities
- Our Founders
- Our Leadership
- What makes us different



Ami Organics – At a Glance

- One of the leading Research and Development driven manufacturer of Specialty Chemicals
- Focused on the development and manufacturing of:
 - Advanced Pharmaceutical Intermediates
 - Specialty Chemicals
- Serves diverse end-use industries including Pharmaceuticals, Cosmetics, Fine Chemicals, Semiconductor, Battery Chemicals, among others

7,250

FY24 Total Revenue
(INR mn)

1,285

FY24 EBITDA
(INR mn)

808

FY24 Adj. PAT
(INR mn)

500+

Customers

~45

Countries
(Customer locations)

56%

Export%
(FY24)

4

Manufacturing
Facilities
(Gujarat, Uttar Pradesh)


1

R&D Facility
State of art in-house R&D facility
recognized by DSIR in Gujarat

Business Segments




**Advanced Pharmaceutical
Intermediates**




**Specialty
Chemicals**

Revenue Mix (FY24)



**Advanced Pharmaceutical
Intermediates**




**Specialty
Chemicals**

570+ Products

Invoiced to customers in last 5 years

The Evolution




Note: HSE - Health, Safety and Environment; ETP - Effluent Treatment Plant; RM - Raw Material; EIR - Establishment Investigation Report



Advanced Pharmaceutical Intermediates

- ~**550 Products** invoiced in last 5 years
- Intermediates across **17+ therapeutic areas**
- ~**95% Chronic Therapy** focus
- Majorly backward integrated to **Basic Chemical** level
- **Market leader for key intermediates across the globe**



Specialty Chemicals

- **Parabens & Paraben formulations**
- **Methyl Salicylate**
- Niche **KSMs** for cosmetics, finechem and agrochem companies
- **Semiconductor Chemicals** business through **Baba Fine Chemicals - Only Indian player in Photo Resist Chemicals**
- **Electrolyte additives** used in manufacturing cells for energy storage devices - **First Company in India to manufacture electrolyte additives**

Strong and Long-term Relations with Diversified Customers across Geographies

500+

Customers

~45


Countries
(customer locations)

30+


Customers associated
since last 10 years

- Well established long-term relations with domestic customers as well as MNCs across large and fast-growing markets
- Diversified customer base
- Long term supply contract with key customers
- Prolonged adherence to stringent client requirements leading to new business from existing customers as well as from new clients


Global Customer Base Spread across...



Export Revenue



Key Export Destinations (FY24)



Strong and Long-term relations with Diversified Customers across Geographies (cont'd)

Advanced Pharma Intermediates (Top Clients)

Generic



Innovators



Specialty Chemicals (Top Clients)

State-of-the-Art Manufacturing Facilities

76,891
Total Land Area (sq mtrs)

~1,100
Total Installed Capacity (KL)

Sachin, Gujarat



Land Area (sq mtrs) **Installed Capacity (KL)**

8,250 **144**

- Multipurpose facility equipped for production of advanced pharmaceutical intermediates
- One block with 13 separate product lines, 40 reactors, 17 dryers, zero-liquid discharge based ETP and SBT system

Ankleshwar, Gujarat



Land Area (sq mtrs) **Installed Capacity (KL)**

10,375 **442**

- Inaugurated in Dec 2023, for production of advanced pharmaceutical intermediates
- Three blocks with 80+ reactors, ~35 dryers, ETP system
- Automated plant with Fully operational DCS (Distributed Control System) and PTS (Powder Transfer System)

Jhagadia, Gujarat



Land Area (sq mtrs) **Installed Capacity (KL)**

56,998 **512**

- Multipurpose facility for production of parabens, methyl salicylate and other specialty chemicals
- Consists of 26 stainless steel and glass reactors with fully dedicated lines for paraben and ,ethyl salicylate production
- Equipped with state of art ETP treatment facility
- Unused 15,830 sq mtrs land available to explore brownfield expansion opportunities

Greater Noida, UP



Land Area (sq mtrs) **Installed Capacity (KL)**

999 **1.8**

- Manufacturing of electronic grade photo resist chemicals
- 7 lab room with glass line capacity of 500 litres and 14 glass assembly with capacity of 1,300 litres



Note: ETP - Effluent Treatment Plan; SBT - Soil Bio Technology

R&D Centric Organization...

1 R&D Lab

23,681 sq. ft.

State of art R&D facility at Sachin supported by an ADL

2 Technology

ADL fully supported by analytical instruments like:

- LCMASS
- GCMASS
- UV spectrophotometer
- Photo stability & stability chambers, etc.

3 State-of-the-Art Equipment

- Modern fume hood system
- Autoclave
- High vacuum distillation assembly
- Glass reactor assembly, etc.

4 R&D Strategy

R&D team focused on:

- NCE product
- New product development
- Process improvement

5 Team

Specialized team of 110+ members including:

- 11 Ph.Ds
- 18 Engineers

6 Patents

15 process patents filed for advanced pharma intermediates:


- 10 patents granted
- 1 patent published
- 4 in process of examination

R&D Expenditure

(INR mn)


65	70	77	141	62
----	----	----	-----	----

R&D expenditure as % of Revenue from Operations



Superior R&D Capabilities (Cont'd)

Our Capabilities in Key Chemistry



**AMI Organics R&D
Centre in Surat**



Continuous Flow Reactor

- Continuous flow reactors are **more efficient, and sustainable** when compared to manufacturing products using traditional reactors.
- Successfully developed capabilities in **Plug Flow, Catalytic fixed-bed flow, Tubular flow** kind of reactors
- This technology **reduces the cycle time to manufacture** a product which leads to **lower utilization of utilities**
- The space required to fit a flow reactor is considerably lower than the traditional reactors.
- Successfully developed and **commercialized Chlorination, Nitration, Etherification, Ammoxidation, Diazotization and Oxidation in flow reactor**
- Successfully **commissioned Photo Chlorination and Grignard in pilot flow reactor**



Our Founders



Nareshkumar Patel

Executive Chairman, MD

- Mr. Nareshkumar Patel is founder of the Company
- He has been associated with the Company since its inception and has extensive experience in the global generic pharma business
- He is responsible for handling the Chemical Engineering and Product Implementation divisions of the Company
- He holds a Bachelor degree in Engineering from Gujarat University

- Mr. Chetankumar Vaghasia is one of the co-founders of the Company
- He has been associated with the Company since its inception and has deep experience in the chemical industry
- He is responsible for handling the Procurement and Administration divisions of the Company
- He holds a Diploma in Man-made Textile Processing from Surat, Gujarat



Chetankumar Vaghasia

Whole – time Director

Our Leadership

Board of Directors



Virendra Mishra

Whole – time Director

- Holds Master of Science degree
- Previously associated with K.A. Malle Pharmaceuticals and Surya Organics & Chemicals



Girikrishna Maniar

Non – executive, Independent Director

- Holds a Bachelor of Science degree and is a fellow member of the Institute of Cost Accountants of India



Richa Goyal

Non – executive, Independent Director

- Holds Bachelor of Commerce degree and an LLB degree; Fellow member of the Institute of Company Secretaries of India
- Currently associated with “Richa Goyal and Associates”



Hetal Gandhi

Non – executive Independent Director

- 34+ years of experience in the financial services industry
- Holds Bachelor of Commerce degree and is an Associate Member of the ICAI
- Co-founder and MD of Tano India Advisors



Dr. Anita Bandyopadhyay

Independent Director

- Acclaimed HR consultant with extensive expertise in Leadership Development and Talent Management
- Holds a Doctorate in Applied Psychology from Kolkata University
- She has experience in Pharma, FMCG, Retail, and B2B business sectors



Mr. Ram Mohan Lokhande

Whole – time Director

- Holds B.E. Chemicals from NIIT, Warangal
- 20+ years of vast experience with leading pharmaceutical and chemical companies
- Previously associated with Glenmark Pharmaceuticals, Dr. Reddy Laboratories and Macleod’s Pharmaceuticals

Senior Management Personnel

Bhavin Shah

Chief Financial Office

- Holds Bachelor of Commerce degree and is a qualified Chartered Accountant from ICAI
- Previously associated with Sun Pharma Group and Deloitte Haskins & Sells

Ajit Kumar Choubey

President – Technical

- Holds Doctor of Philosophy degree in Chemistry
- Previously associated with IPCA Laboratories

Hemant Patel

SGM – Human Resource

- Holds Master of Labour Management and Post Graduate Diploma in Personnel Management and Industrial Relations

Sanjay Vasoya

AVP – R&D

- Holds Ph.D. and M.Sc in Organic Chemistry
- Previously associated with Teva Pharmaceuticals, Alembic and Rubamin Pharma

Gaurav Bhandari

Senior Manager – Marketing

- Holds Bachelor of Technology (Bioinformatics) and PGDM degree
- Previously associated with Go Zoop Online Pvt Ltd and Social PR Outsourcing Pvt Ltd

What Makes Us Different ?



Niche Product Portfolio with a Strong Market Share

- Niche products with limited competition focused on the chronic disease market
- Market leader for the key intermediates across the globe



High Entry Barriers

- A long gestation period to be enlisted as a supplier
- The involvement of complex chemistries
- Regulatory requirements creating hurdles for new entrants



Diversified Products to Support Future Growth

- A long tail of 570+ products which includes products that are in development or testing phase, some of which have the potential to support our growth in coming years



Diversified Customer Base across Geographies

- Successful track record of working with innovators with sticky customers across products
- Trusted and reliable supplier of intermediates globally
- "Preferred Supplier" status for key molecules



Reputation for Innovative Product Launches Supported by Robust R&D

- First to Market in most of the products
- For a single intermediate, capability to provide product from N-1 to N-12 stage with different routes of synthesis




Robust Cost Management / Process Improvements

- ~71% of raw material outsourced from domestic vendors
- Continuous focus on process optimization and improvement has led to cost leadership in the industry with high quality products
- Focus on newer technologies to manufacture products e.g. – continuous flow processes

3. Advanced Pharma Intermediate

- A leading Advanced Intermediate Manufacturer from India
- Our Business Model
- Uniqueness of our business model
- Our Strategy and Outlook
- Industry Overview



Advanced Pharmaceutical Intermediates



5,678
FY24
Revenue
(INR mn)



17+
Therapeutic
Areas



150+
Customers
in FY24



25+
Countries
(Customer locations)




15
Process Patents
(1 patent published; 10
patents granted and 4 patents
applied)




2
Manufacturing
Facilities
Surat and Ankleshwar, Gujarat
(Ankleshwar plant is under
development)

Historical Business Performance


(INR mn)



Segment Revenue



Our Business Model – Advanced Intermediates for Pharmaceuticals



CDMO

- Contract Manufacturing for big pharma companies
- Exclusive long term supply contracts



Regulatory market business


- Supplying NCE molecules to the pharma innovator companies
- Supplying intermediates to the innovator pharma companies for the products under patent
- Supplying intermediates to the innovator pharma companies for the off-patent products



Emerging market business

- Supplying intermediates to the generic API manufacturer
- First mover advantage
- Sustaining market through Cost efficiency

Uniqueness of our business model



Chronic Therapy focused

- ~95% of the products catered on fast-growing Chronic segment

Wide Product Basket

- Wider basket of products, with 550+ molecules

R&D Leadership

- First to market with target products
- Products available with different routes of synthesis
- Capabilities to furnish products from n-1 to n-12 stages

Presence across value chain

- AMI is present across the value chain of the intermediates business, from supplying NCE to innovators, providing a wide range of products with the different routes of synthesis and different levels of intermediates


Preferred Supplier

- Our unique business model positions us perfectly to be the preferred suppliers for the innovators as well as big generic pharma companies

Strong Customer Base

- As one of the biggest manufacturers of intermediates for the target therapies, AMI is in a unique position to cross-sale new molecules to existing clients.
- AMI has more than 1 product with all major customers


Our Strategy – Advanced Pharmaceutical Intermediates



Industry Overview (1/2)


Global API Market

(USD bn)






Global Pharmaceutical Intermediates Market

(USD bn)



Global API Market Split by Therapy



	CAGR (2018-23)	CAGR (2023-28E)
Oncology	11%	13%
Cardiovascular	4%	5%
CNS	6%	5%
Anti-Infective	4%	5%
Immunology	8%	9%
Endocrinology	8%	7%
Anti-Coagulant	8%	8%
Gastrointestinal	4%	5%
Anti-Depressant	4%	3%
Parkinson's Disease	7%	8%

■ Oncology ■ Cardiovascular ■ CNS ■ Anti-Infective ■ Immunology ■ Endocrinology ■ Anti-Coagulant ■ Gastrointestinal ■ Anti-Depressant ■ Parkinson's Disease ■ Others

4. Specialty Chemicals

- Speciality Chemicals - Overview
- Our Strategy and Outlook
- Industry Overview



Speciality Chemicals



1,497
FY24
Revenue
(INR mn)



3
Business
Segments

- Specialty Chemicals for various industries e.g. Cosmetics, Finechem, Agrochem, etc.
- Battery Chemicals
- Semiconductor Chemicals



40+
Products



340+
Customers



40+
Countries
(Customer locations)




2
Manufacturing
Facilities


Jhagadia, Gujarat and Greater Noida, Uttar Pradesh

Historical Business Performance


(INR mn)



Segment Revenue




Our Strategy – Speciality Chemicals



Industry Overview (2/2)


Global Specialty Chemicals Market

(USD bn)




Global Electrolyte Additives and Electrolyte Solutions Market

(USD bn)



Global Photoresist Chemicals and Semiconductor Chemicals Market

(USD bn)



5. Working towards better tomorrow



ESG Focus – Working towards a Better Tomorrow



Environment

- Zero Liquid Discharge based in-house effluent plant at Sachin facility
- 80% of wastewater recycled
- Developing greenbelt in Sachin
- All the manufacturing units are ISO 9001:2015, ISO 14001:2015 certified
- Awarded Gold Rating accreditation from EcoVadis, recognizing the company's outstanding commitment to sustainability



Social

- Company's Sachin facility is SA 8000:2014 certified
- The SA8000® standard is the leading social certification standard for factories and organizations across the globe
- Occupational health and safety management system at Sachin facility has been certified to be in compliance with ISO 45001:2018 standards by the Bureau Veritas Certification Holding SAS – UK Branch



Governance

- 50% of the board constitutes of independent directors
- Audit and Nomination and Remuneration Committee are headed by independent directors

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from AMI Organics Ltd.

Contact Us

For more information please contact:



Ami Organics Limited

Ekta Srivastava

Company Secretary & Compliance Officer

cs@amiorganics.com

Rahul Thakur

Senior Manager – Investor Relations

Rahul.thakur@amiorganics.com

